ライフサイエンスコーパス: carcinoembryonic antigen

1 irally encoded marker peptide (soluble human carcinoembryonic antigen).

2 were monitored for 3 mo using PET and serum carcinoembryonic antigen.

3 treatment of solid cancers known to produce carcinoembryonic antigen.

4 aving recurrence based on elevated levels of carcinoembryonic antigen.

5 ., human prostate-specific antigen and human carcinoembryonic antigen.

6 ptase polymerase chain reaction (RT-PCR) for carcinoembryonic antigen.

7 ltaneous detection of cancer antigen 125 and carcinoembryonic antigen.

8 l antibody specific for the tumor-associated carcinoembryonic antigen.

9 onal antibody (MAb) chimeric T84.66, against carcinoembryonic antigen.

10 h node metastasis status and serum levels of carcinoembryonic antigen.

11 d Raman scattering detection of the targeted carcinoembryonic antigen.

12 nosensor was fabricated for the detection of carcinoembryonic antigen.

13 recurrence were not significantly different: carcinoembryonic antigen (29.1% v 37.4%), computed tomog

14 biomarkers performed better than cyst fluid carcinoembryonic antigen (37%/80% sensitivity/specificit

15 Finally, SV40 LT-positive carcinoma of carcinoembryonic antigen 424/SV40 LT transgenic mice dis

16 he accuracy of standard analyses: cyst fluid carcinoembryonic antigen (61%; 95% CI, 46% to 74%; P < .

17 Nested RT-PCR that used primers for carcinoembryonic antigen, a marker for colorectal cancer

18 bserved radiation-induced down-regulation of carcinoembryonic antigen, a prototypic cancer biomarker.

19 Carcinoembryonic antigen-A2Kb (CEA-A2Kb) double transgen

20 Monitoring of serum carcinoembryonic antigen after primary resection of colo

21 rum biomarker assay, we determined levels of carcinoembryonic antigen, alpha1-antitrypsin, and squamo

22 tations or preoperative cyst fluid analysis (carcinoembryonic antigen, amylase, or mucin presence).

23 positive for each antigen (HT-1080(CEA) for carcinoembryonic antigen and A431 for EGF receptor), and

24 ed at multiple levels and stained using anti-carcinoembryonic antigen and anticytokeratin antibodies.

25 determine use of tumor marker tests such as carcinoembryonic antigen and CA 15-3/CA 27.29 and associ

26 ERCP), spiral computed tomography, and serum carcinoembryonic antigen and CA19-9 analysis were perfor

27 Carcinoembryonic antigen and cancer antigen 15-3 concent

28 ic cancers, elevated pre-operative levels of carcinoembryonic antigen and carbohydrate antigen (CA) 1

29 astic lesions, compared with 35% and 50% for carcinoembryonic antigen and cytology ( P < .001 and P =

30 ins) targeting two different tumor antigens (carcinoembryonic antigen and EGF receptor).

31 antigen (PSA), PSA-alpha1-antichymotrypsin, carcinoembryonic antigen and mucin-1, including detectio

32 v-Fc variants with specificity for the tumor carcinoembryonic antigen and mutations in the FcRn-bindi

33 d clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene e

34 Billing dates of STMs (carcinoembryonic antigen and/or cancer antigen 15-3/canc

35 ncluding measurement of serum calcitonin and carcinoembryonic antigen (and their doubling times), in

36 therapy responses were assessed by CT, serum carcinoembryonic antigen, and calcitonin.

37 fferentiation markers (alkaline phosphatase, carcinoembryonic antigen, and E-cadherin).

38 sion of liver cell markers cytokeratin 8 and carcinoembryonic antigen, and in some cells the liver st

39 as a 40-kilodalton band distinct from mucin, carcinoembryonic antigen, and Mac-2 binding protein.

40 lycosylation of mucin (MUC)1, MUC5AC, MUC16, carcinoembryonic antigen, and other proteins implicated

41 Antibodies targeting carcinoembryonic antigen (Anti-CEA) were immobilized to

42 erapy, using a humanized (131)I-labeled anti-carcinoembryonic antigen antibody ((131)I-huA5B7), with

43 s included colorectal cancer, follow-up, and carcinoembryonic antigen, as well as the names of the sp

44 ory/inhibitory molecules, including Ox40 and carcinoembryonic antigen-associated cell adhesion molecu

45 Here, we address these issues for the anti-carcinoembryonic antigen bifunctional antibody-hapten an

46 f the largest metastatic tumor, preoperative carcinoembryonic antigen, bilateral resection, extensive

47 ologue of CEACAM1 and that rabbit anti-human carcinoembryonic antigen blocks NTHI colonization of the

48 agnetic resonance imaging, or tumor markers (carcinoembryonic antigen, CA 15-3, and CA 27.29) is not

49 tic resonance imaging, and/or tumor markers (carcinoembryonic antigen, CA 15-3, and CA 27.29) is not

50 Carcinoembryonic antigen, cancer antigen 15-3, and cance

51 hs, hematologic blood counts, tumor markers (carcinoembryonic antigen, cancer antigen [CA] 15-5, and

52 h peptides from corresponding tumor antigen (carcinoembryonic antigen, CD55, and human high molecular

53 Lymphovascular invasion, preoperative serum carcinoembryonic antigen (CEA > 5 ng/mL) level, and age

54 used consisted of mice transgenic for human carcinoembryonic antigen (CEA) and a murine carcinoma ce

55 ted with TF2--a recombinant, humanized, anti-carcinoembryonic antigen (CEA) and anti-histamine-succin

56 In addition to carcinoembryonic antigen (CEA) and CA 15-3, CA 27.29 was

57 hemin aptamer), capable of rapidly capturing carcinoembryonic antigen (CEA) and hemin, an all-in-one

58 Promoters for the human carcinoembryonic antigen (CEA) and MUC1/DF3 tumor-associ

59 We and others have found high levels of carcinoembryonic antigen (CEA) and prostate-specific ant

60 tastatic cancer expressing the tumor antigen carcinoembryonic antigen (CEA) and that it overcame high

61 ed the Fc-FcRn binding site of chimeric anti-carcinoembryonic antigen (CEA) antibodies produced in a

62 In this study, we used an anti-carcinoembryonic antigen (CEA) antibody (MN-14) tagged w

63 For example, 2 identical Fabs reacting with carcinoembryonic antigen (CEA) are bound to a Fab reacti

64 Using carcinoembryonic antigen (CEA) as a model analyte, the p

65 Our goal was to use carcinoembryonic antigen (CEA) as a target for immunothe

66 Mice expressing human carcinoembryonic antigen (CEA) as a transgene (CEA.Tg) d

67 protein biomarker in undiluted serum, using carcinoembryonic antigen (CEA) as the test case.

68 and absolute costs of physician examination, carcinoembryonic antigen (CEA) assessment, chest x-ray,

69 or colorectal cancer, it is recommended that carcinoembryonic antigen (CEA) be ordered preoperatively

70 l line LS174T, while measuring the biomarker carcinoembryonic antigen (CEA) before and after the use

71 h prognostic factors as serum calcitonin and carcinoembryonic antigen (CEA) doubling times (DTs).

72 Calcitonin and carcinoembryonic antigen (CEA) doubling times are curren

73 As a tumor marker for colorectal cancers, carcinoembryonic antigen (CEA) enhances the metastatic p

74 l line specific for a MHC class I-restricted carcinoembryonic antigen (CEA) epitope, residues 526-533

75 Carcinoembryonic antigen (CEA) expression is used clinic

76 Biliary glycoproteins are members of the carcinoembryonic antigen (CEA) family and behave as cell

77 late (non-typeable) H. influenzae target the carcinoembryonic antigen (CEA) family of cell adhesion m

78 For the human carcinoembryonic antigen (CEA) family, a subfamily of th

79 CEACAM1 is a member of the carcinoembryonic antigen (CEA) family.

80 biliary glycoprotein (Bgp) subfamily of the carcinoembryonic antigen (CEA) family.

81 The release of soluble antigens, such as carcinoembryonic antigen (CEA) from colorectal carcinoma

82 When transgenic mice that express the human carcinoembryonic antigen (CEA) gene (CEA transgenic) wer

83 typic cell adhesion protein belonging to the carcinoembryonic antigen (CEA) gene family and expressed

84 atitis virus (MHV) are members of the murine carcinoembryonic antigen (CEA) gene family.

85 Mice transgenic for the human carcinoembryonic antigen (CEA) gene were prepared for us

86 , a label-free sensitive assay for detecting carcinoembryonic antigen (CEA) in a continuous and recyc

87 mplicated the surface glycoproteins CD44 and carcinoembryonic antigen (CEA) in adhesion, migration, a

88 experiment, detection of a cancer biomarker carcinoembryonic antigen (CEA) in blood plasma using ant

89 using an SPR biosensor for the detection of carcinoembryonic antigen (CEA) in which AuNPs covered wi

90 we demonstrate that, in addition, the 180-kD carcinoembryonic antigen (CEA) is a receptor for Opa pro

91 Carcinoembryonic antigen (CEA) is a tumor marker that is

92 Carcinoembryonic antigen (CEA) is a tumor-associated ant

93 Carcinoembryonic antigen (CEA) is a tumor-associated ant

94 Human carcinoembryonic antigen (CEA) is a well-characterized o

95 By virtue of its tissue-specific expression, carcinoembryonic antigen (CEA) is an important self, tum

96 Human carcinoembryonic antigen (CEA) is an oncofetal glycoprot

97 Carcinoembryonic antigen (CEA) is highly expressed on th

98 Patients with a carcinoembryonic antigen (CEA) less than 200 ng/mL had i

99 proposed the inclusion of pretreatment serum carcinoembryonic antigen (CEA) levels (C stage) into the

100 Surgical margin, number of lesions, and carcinoembryonic antigen (CEA) levels significantly cont

101 Median total bilirubin, CA19-9, and carcinoembryonic antigen (CEA) levels were 0.6 mg/dL, 15

102 caled-up radioiodination of a humanized anti-carcinoembryonic antigen (CEA) mAb, humanized MN-14 (hMN

103 Carcinoembryonic antigen (CEA) may promote experimental

104 mor targeting using a non-internalizing anti-carcinoembryonic antigen (CEA) monoclonal antibody (mAb)

105 or activity, of the 131I-labeled murine anti-carcinoembryonic antigen (CEA) monoclonal antibody, NP-4

106 als or from cancer patients transfected with carcinoembryonic antigen (CEA) mRNA stimulate a potent C

107 We evaluated recombinant MV-Edm expressing carcinoembryonic antigen (CEA) or the human sodium iodid

108 we investigated the use of an enhanced human carcinoembryonic antigen (CEA) promoter for yeast cytosi

109 arget therapy to colorectal cancer using the carcinoembryonic antigen (CEA) promoter have demonstrate

110 .1-30 ng/mL) and highly (>30 ng/mL) elevated carcinoembryonic antigen (CEA) serum levels were both pr

111 We studied the behavior of three anti-carcinoembryonic antigen (CEA) single-chain Fv-Fc (scFv-

112 study, we investigated the 18F-labeled anti-carcinoembryonic antigen (CEA) T84.66 diabody, a genetic

113 ween sensitivity and specificity at specific carcinoembryonic antigen (CEA) thresholds for detecting

114 ectal cancer was generated by crossing human carcinoembryonic antigen (CEA) transgenic mice (H-2K(b))

115 and replication-defective avipox recombinant carcinoembryonic antigen (CEA) vaccines has demonstrated

116 Then the carcinoembryonic antigen (CEA) was immobilized between t

117 een patients with advanced tumors expressing carcinoembryonic antigen (CEA) were randomized to receiv

118 mino-terminal domain is highly homologous to carcinoembryonic antigen (CEA), a glycophosphatidyl inos

119 ingle-chain Fv antibody (ScFvT84.66) against carcinoembryonic antigen (CEA), a well characterized tum

120 al detection system, four cancer biomarkers: carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP),

121 sensing (IMS) platforms for the detection of carcinoembryonic antigen (CEA), an implicated tumor biom

122 sfusion, liver resection type, pre-resection carcinoembryonic antigen (CEA), and previous hepatectomy

123 d the immunogenicity of the nominal antigen, carcinoembryonic antigen (CEA), and that of an anti-idio

124 t as low as 16 pM Ebola Virus DNA, 0.01ng/mL carcinoembryonic antigen (CEA), and the 10 HER2-expressi

125 function test, and serum biomarkers such as carcinoembryonic antigen (CEA), bilirubin, alpha fetopro

126 y targeting dually acylated proteins (namely carcinoembryonic antigen (CEA), CD36, and the NH(2)-term

127 body 3H1, which mimics a specific epitope of carcinoembryonic antigen (CEA), has the potential to bre

128 he use of MVA encoding a tumor antigen gene, carcinoembryonic antigen (CEA), in addition to multiple

129 Membrane proteins, CD44, carcinoembryonic antigen (CEA), podocalyxin-like protein

130 Here we show that tolerance to carcinoembryonic antigen (CEA), which is overexpressed b

131 geting a multivalent, bispecific antibody to carcinoembryonic antigen (CEA), which subsequently also

132 In this study, using the carcinoembryonic antigen (CEA)-expressing C15 murine col

133 antitumor immune responses in patients with carcinoembryonic antigen (CEA)-expressing malignancies b

134 tion increased Fas (CD95) gene expression in carcinoembryonic antigen (CEA)-expressing murine tumor c

135 e (177)Lu is an attractive approach to treat carcinoembryonic antigen (CEA)-expressing tumors.

136 cognizes decay-accelerating factor (DAF) and carcinoembryonic antigen (CEA)-related cell adhesion mol

137 Carcinoembryonic antigen (CEA)-related cell adhesion mol

138 arrhalis share the property of targeting the carcinoembryonic antigen (CEA)-related cell adhesion mol

139 Carcinoembryonic antigen (CEA)-related cell adhesion mol

140 Although carcinoembryonic antigen (CEA)-related cell adhesion mol

141 nding to decay-accelerating factor (DAF) and carcinoembryonic antigen (CEA)-related cell surface prot

142 Optimal stimulation of carcinoembryonic antigen (CEA)-specific CTLs by peptide-

143 en express both cyclooxygenase-2 (COX-2) and carcinoembryonic antigen (CEA).

144 es more than that obtained by assaying serum-carcinoembryonic antigen (CEA).

145 ingle-chain Fv (scFv) antibody reactive with carcinoembryonic antigen (CEA).

146 ometry, we identify this glycoprotein as the carcinoembryonic antigen (CEA).

147 mors (e.g., colon, lung, and breast) express carcinoembryonic antigen (CEA).

148 target cells expressing the tumor-associated carcinoembryonic antigen (CEA).

149 e lineage, genetically engineered to produce carcinoembryonic antigen (CEA).

150 ough its high affinity for the tumour marker carcinoembryonic antigen (CEA).

151 The tumor antigen used was human carcinoembryonic antigen (CEA).

152 (KC) that encodes a protein interacting with carcinoembryonic antigen (CEA).

153 ody (scAb) specific for the tumor-associated carcinoembryonic antigen (CEA).

154 The model tumor antigen used was carcinoembryonic antigen (CEA).

155 these studies was the tumor-associated human carcinoembryonic antigen (CEA).

156 identify HL4-B7-restricted CTL epitopes for carcinoembryonic antigen (CEA).

157 ox vaccine containing the gene for the human carcinoembryonic antigen (CEA).

158 ted CeaVac, that is an internal image of the carcinoembryonic antigen (CEA).

159 [-1]) IgG1 monoclonal antibody (MAb) against carcinoembryonic antigen (CEA).

160 (11) M(-1)) IgG1 monoclonal antibody against carcinoembryonic antigen (CEA).

161 ecific cross-reacting antigen related to the carcinoembryonic antigen (CEA).

162 c HLA-A2+-binding peptide derived from human carcinoembryonic antigen (CEA).

163 sensitive detection of the tumor biomarker, carcinoembryonic antigen (CEA).

164 ribed for detecting cancer-related biomarker carcinoembryonic antigen (CEA).

165 positron emission tomographic (PET) scan or carcinoembryonic antigen (CEA).

166 Carcinoembryonic antigen (CEA, CD66e, CEACAM-5) is a cel

167 a polyclonal antibody directed against human carcinoembryonic antigens (CEA) or with some monoclonal

168 eLa cells transfected with cDNA encoding the carcinoembryonic antigen [CEA (CD66e)] subgroup of the C

169 In patients with occult disease (increasing carcinoembryonic antigen [CEA] titer, negative diagnosti

170 The carcinoembryonic antigen (CEAs) family consists of a lar

171 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACA

172 CEACAM1-4S (carcinoembryonic antigen cell adhesion molecule 1, with

173 Costimulation with catecholamines, carcinoembryonic antigen cell adhesion molecule 8 (CEACA

174 Carcinoembryonic antigen cell adhesion molecule like I (

175 e epithelial cell adhesion molecule CEACAM1 (carcinoembryonic antigen cell adhesion molecule-1) is do

176 Based on the absence in mice of human carcinoembryonic antigen cell adhesion molecules, the ma

177 antigen, prostate-specific membrane antigen, carcinoembryonic antigen, CK-19, CK-20, mucin 1, and GA7

178 immunohistochemical markers (polyclonal anti-carcinoembryonic antigen, CK7, CK20, and alpha-fetoprote

179 care (computed tomography scan, preoperative carcinoembryonic antigen, clear surgical margins, medica

180 e-chain antibodies (scAs) directed against a carcinoembryonic antigen-cross-reacting cell surface pro

181 ed for comparison, including polyclonal anti-carcinoembryonic antigen, cytokeratin (CK) 7, CK20, and

182 Baseline plasma carcinoembryonic antigen/cytokeratin 19 fragments biomar

183 able binding isotherm, from which an in vivo carcinoembryonic antigen density of 0.56 nmol/g (5.0 x 1

184 onstrated an increase in Ca(2+)-independent, carcinoembryonic antigen-dependent homotypic aggregation

185 -principle analytes include FLAG peptide and carcinoembryonic antigen detected at physiologically rel

186 More than 80% of patients had preoperative carcinoembryonic antigen determination (ie, stages II to

187 1)In-DOTA-polyethylene glycol (PEG)3400-anti-carcinoembryonic antigen diabody has less than half the

188 nded for use in practice: CA 15-3, CA 27.29, carcinoembryonic antigen, estrogen receptor, progesteron

189 ntly at the discretion of the physician; and carcinoembryonic antigen every 3 months postoperatively

190 showed good performance in the detection of carcinoembryonic antigen, exhibiting a simple, rapid and

191 e responses were induced in a patient with a carcinoembryonic antigen-expressing adenocarcinoma after

192 ugate was 8 times more cytotoxic against two carcinoembryonic antigen-expressing carcinoma cell lines

193 Furthermore, other carcinoembryonic antigen-expressing malignancies could a

194 bind heparan sulfate proteoglycan (HSPG) or carcinoembryonic antigen family (CEACAM) receptors on hu

195 in vivo, the canonical receptor for MHV, the carcinoembryonic antigen family member CEACAM1a, has bee

196 CD66 antigens, or carcinoembryonic antigen family members, constitute a fa

197 P, C-CAM, CD66a, or MHVR) are members of the carcinoembryonic antigen family of cell adhesion molecul

198 Additionally, three different genes of the carcinoembryonic antigen family were induced by PPARgamm

199 the immunoglobulin (Ig) superfamily and the carcinoembryonic antigen family.

200 The vertebrate-restricted carcinoembryonic antigen gene family evolves extremely r

201 ors (CAR) specific for either hPSMA or human carcinoembryonic antigen (hCEA) and with a fusion report

202 % CI = 1.4418-6.905, P < 0.001, Preoperative carcinoembryonic antigen HR = 2.359, 95% CI = 1.0203-5.4

203 An anti--carcinoembryonic antigen IgG antibody (MN14) was conjuga

204 n microarrays were demonstrated by detecting carcinoembryonic antigen in human plasma samples.

205 g of single-chain antibody fragments against carcinoembryonic antigen in LS174T tumor spheroids.

206 r the early detection of a cancer biomarker, carcinoembryonic antigen, in the sera of mice bearing a

207 Although cyst fluid carcinoembryonic antigen is a very good marker for the p

208 largest hepatic tumor >5 cm (p = 0.01), and carcinoembryonic antigen level >200 ng/ml (p = 0.01).

209 Tumor size > or =5 cm, >3 tumor nodules, and carcinoembryonic antigen level >200 ng/mL predicted poor

210 dictors of pathologic response revealed that carcinoembryonic antigen level < or = 5 ng/mL, tumor siz

211 by follow-up testing (36 patients), elevated carcinoembryonic antigen level (41 patients), or symptom

212 were tumor size larger than 3 cm (P = .005), carcinoembryonic antigen level greater than 30 ng/mL (P

213 such as tumor-to-liver volume ratio or serum carcinoembryonic antigen level, and does not correlate t

214 erval, ploidy, differentiation, preoperative carcinoembryonic antigen level, and operative factors su

215 a mild but significant correlation to serum carcinoembryonic antigen levels and tumor-to-liver volum

216 occult disease recurrence and elevated serum carcinoembryonic antigen levels at the time of the repea

217 otherapy utilization, metastases number, and carcinoembryonic antigen levels were similar.

218 ffective for managing patients with elevated carcinoembryonic antigen levels who were candidates for

219 logic factors, such as number of lesions and carcinoembryonic antigen levels, determine potential cur

220 at the 500-mg bid dose had a 46% decrease in carcinoembryonic antigen levels, improvement in cough, a

221 patients showed a similar reduction in serum carcinoembryonic antigen levels.

222 ctural changes within the genomic cluster of carcinoembryonic antigen-like cellular adhesion molecule

223 ther with tumor antigens such as survivin or carcinoembryonic antigen, markedly activate both innate

224 otential of high-dose 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody (MAb) combi

225 osimetry of 188Re-labeled MN-14, an IgG anti-carcinoembryonic antigen monoclonal antibody (MAb), were

226 , a marker for colorectal cancer, identified carcinoembryonic antigen mRNA in lymph nodes from only 1

227 engineered MV to express the marker peptide carcinoembryonic antigen (MV-CEA virus) to also permit r

228 ) specific for the designated receptor human carcinoembryonic antigen on the TPMV H ectodomain.

229 sion glycolysis, or change in serum level of carcinoembryonic antigen or carbohydrate antigen 19-9 fr

230 and number of organs involved (but not PSA, carcinoembryonic antigen, or neuroendocrine markers) wer

231 phic response (P < 0.001), decrease in serum carcinoembryonic antigen (P < 0.05), and overall surviva

232 ated with the CEA immunodominant CTL epitope carcinoembryonic antigen peptide-1 and interleukin 2 and

233 es (bsAbs) for disease-specific targeting of carcinoembryonic antigen-positive cells and recognition

234 Fifteen patients with at least one carcinoembryonic antigen-positive lesion were evaluated.

235 CEA (carcinoembryonic antigen) protein and c-DNA were detecte

236 these patients had a tumor as well as plasma carcinoembryonic antigen reduction from baseline after l

237 Here we have identified carcinoembryonic antigen- related cell adhesion molecule

238 target an important human cellular receptor carcinoembryonic antigen-related cell adhesion molecule

239 Liver-specific inactivation of carcinoembryonic antigen-related cell adhesion molecule

240 d insulin clearance, in liver-specific S503A carcinoembryonic antigen-related cell adhesion molecule

241 Liver-specific inactivation of carcinoembryonic antigen-related cell adhesion molecule

242 CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

243 udies suggest an important role for CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

244 Previously, we have demonstrated carcinoembryonic antigen-related cell adhesion molecule

245 Carcinoembryonic antigen-related cell adhesion molecule

246 ding of viral spike (S) proteins to cellular carcinoembryonic antigen-related cell adhesion molecule

247 Down-regulation of carcinoembryonic antigen-related cell adhesion molecule

248 Carcinoembryonic antigen-related cell adhesion molecule

249 fat diet reduces the expression of CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

250 Carcinoembryonic antigen-related cell adhesion molecule

251 Overexpression of carcinoembryonic antigen-related cell adhesion molecule

252 a 3D model of breast morphogenesis, CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule

253 ls and virions, peripheral S1 fragments bind carcinoembryonic antigen-related cell adhesion molecule

254 Carcinoembryonic antigen-related cell adhesion molecule

255 such as S100A4, prostate stem cell antigen, carcinoembryonic antigen-related cell adhesion molecule

256 Human carcinoembryonic antigen-related cell adhesion molecule

257 tion with the primary MHV receptor, a murine carcinoembryonic antigen-related cell adhesion molecule

258 p adhesin, exploiting defined members of the carcinoembryonic antigen-related cell adhesion molecule

259 Carcinoembryonic antigen-related cell adhesion molecule

260 Here, we identify members of the carcinoembryonic antigen-related cell adhesion molecule

261 Carcinoembryonic antigen-related cell adhesion molecule

262 Tectorin (TECTA), beta-tectorin (TECTB), and carcinoembryonic antigen-related cell adhesion molecule

263 of Blood, Alshahrani et al demonstrate that carcinoembryonic antigen-related cell adhesion molecule

264 The carcinoembryonic antigen-related cell adhesion molecule

265 itecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule

266 A functional role for the carcinoembryonic antigen-related cell adhesion molecule

267 Carcinoembryonic antigen-related cell adhesion molecule

268 D complexed with its protein receptor murine carcinoembryonic antigen-related cell adhesion molecule

269 c/Akt signaling axis via an interaction with carcinoembryonic antigen-related cell adhesion molecule

270 ter hair cells (OHC) that is a member of the carcinoembryonic antigen-related cell adhesion molecule

271 f MHV NTD complexed with its receptor murine carcinoembryonic antigen-related cell adhesion molecule

272 ptor we used the cell-cell adhesion molecule carcinoembryonic antigen-related cell adhesion molecule

273 The carcinoembryonic antigen-related cell adhesion molecule

274 Although carcinoembryonic antigen-related cell adhesion molecule-

275 Carcinoembryonic antigen-related cell adhesion molecule-

276 Carcinoembryonic antigen-related cell adhesion molecule-

277 Carcinoembryonic antigen-related cell adhesion molecule-

278 ionary origin, and function of rat and human carcinoembryonic antigen-related cell adhesion molecule1

279 -accelerating factor (DAF), collagen IV, and carcinoembryonic antigen-related cell adhesion molecules

280 transcription 1), K16 (keratin 16), CEACAMs (carcinoembryonic antigen-related cell adhesion molecules

281 Carcinoembryonic antigen-related cell adhesion molecules

282 Carcinoembryonic antigen-related cell adhesion molecules

283 hly isolated myeloma cells expressed several carcinoembryonic antigen-related cell adhesion molecules

284 Carcinoembryonic antigen-related cellular adhesion molec

285 Carcinoembryonic antigen-related cellular adhesion molec

286 Immunostains for Hep Par 1 and polyclonal carcinoembryonic antigen remain important cornerstones i

287 Four serum proteins-carcinoembryonic antigen, retinol binding protein, alpha

288 stologically negative LNs by AE1/AE3 IHC and carcinoembryonic antigen RT-PCR.

289 nuclides in the therapy of tumors expressing carcinoembryonic antigen, such as medullary thyroid and

290 ed patient age, tumor location, preoperative carcinoembryonic antigen, T stage, numbers of positive a

291 otocol LTS-01 had a colonoscopy, 88.2% had a carcinoembryonic antigen test, and 66.4% had a computed

292 Medical history, physical examination, and carcinoembryonic antigen testing should be performed eve

293 on-typable (NTHi) H. influenzae target human carcinoembryonic antigens (the membrane associated CEA f

294 iety (monovalent streptavidin or antibody to carcinoembryonic antigen) to label cell-surface proteins

295 yielded exceptional results; mammaglobin and carcinoembryonic antigen transcripts were detected in 10

296 origin [hazard ratio (HR) 2.04, P < 0.001], carcinoembryonic antigen value >/=5 ng/mL at hepatic res

297 L (reference range, 2.14-2.53 mmol/L), and a carcinoembryonic antigen value of 2.69 mug/L (normal val

298 Her carcinoembryonic antigen was 1.1, and all other laborato

299 marker of the secretory cell lineage, since carcinoembryonic antigen, which is expressed in both the

300 e using a multivalent, recombinant anti-CEA (carcinoembryonic antigen) x anti-HSG (histamine-succinyl